The abstract contains a nice, thorough description of the development and validation of Zenith's whole blood pharmacodynamic marker assay for non-invasively measuring target modulation elicited by ZEN-3694. Zenith has previously shared some of this data from patients in the single-agent ZEN-3694 dose escalation. I think all we've seen so far is gene modulation 24 hours after administration of the lowest dose.

In my opinion, this novel PD marker assay could be extremely useful as Zenith proceeds into the later stages of its mCRPC trials and into other oncology indications. This non-invasive assay could really help identify in the early stages of treatment those patients that are responding vs. those that are not. Alternatively, it could help relatively quickly identify which cancers are most responsive to ZEN-3694. 

No new Phase 1 trial data though. The anticipation continues......